Health
Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations – GlobeNewswire
– Second Product Candidate Expected to Enter Clinic in First Half of 2021 – Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal…
Second Product Candidate Expected to Enter Clinic in First Half of 2021
Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal Dementia with Granulin (GRN) Mutations, a Devastating, Progressive Disorder Impacting Adults with No Approved Disease-Modifying Therapy Options
PHILADELPHIA, Jan. 28, 2021 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS)…
-
General16 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
General19 hours agoAlbanese beats drum on economy as trade clouds gather
-
Noosa News18 hours agoSurgeon partner of former premier to testify over his patient’s death
-
Business16 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher